Research programme: small molecule therapeutics - Kallyope
Latest Information Update: 28 Apr 2024
At a glance
- Originator Kallyope
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Migraine; Parkinson's disease
- No development reported Gastrointestinal disorders; Inflammatory bowel diseases; Neurodegenerative disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in Gastrointestinal-disorders in USA
- 28 Apr 2024 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA
- 28 Apr 2024 No recent reports of development identified for research development in Neurodegenerative-disorders in USA